Arterial Revascularisation Trial - a randomised trial to compare survival following bilateral versus single internal mammary artery (IMA) grafting in coronary revascularisation

Conditions

Cardiovascular Circulatory System Arterial revascularisation

David P. Taggart, Mario Gaudino, STEPHEN GERRY, Marek Jasinski, Belinda Lees et al. (56 authors)

JAMA Cardiology2026-09-02

10.1001/jamacardio.2026.3232

Propensity-matched analysis of the impact of saphenous vein graft external stenting on clinical outcomes in coronary bypass surgery: The RESTART study.

Weltert LP, Secemsky EA, Bolotin G, Friedman T, Centofanti P, Sebastiano V, Fusca S, Sandner SE, Pljakova M, Demertzis S, Torre T, Donovan JT, Friedrich I, Li S, Flather M, Gerry S, Taggart DP.

2025-10-24

10.1016/j.xjon.2025.09.048

Minimal clinically important differences in patient-reported outcomes after coronary artery bypass surgery in the arterial revascularization trial

Ruth Masterson Creber, Arnaldo Dimagli, Stephanie Niño de Rivera, David Russell, Stephen Gerry et al. (11 authors)

European Journal of Cardio-Thoracic Surgery2024-06-062 citations

10.1093/ejcts/ezae208

Bilateral versus single internal thoracic coronary artery bypass grafting: the ART RCT

Marcus Flather, Arnaldo Dimagli, Umberto Benedetto, Belinda Lees, Alastair Gray et al. (11 authors)

Efficacy and Mechanism Evaluation2023-10-013 citations

10.3310/jygf5402

Five-year costs from a randomised comparison of bilateral and single internal thoracic artery grafts

Matthew Little, Alastair Gray, Doug Altman, Umberto Benedetto, Marcus Flather et al. (10 authors)

Heart2019-04-044 citations

10.1136/heartjnl-2018-313932

Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years

David P. Taggart, Umberto Benedetto, Stephen Gerry, Douglas G. Altman, Alastair Gray et al. (25 authors)

New England Journal of Medicine2019-01-30453 citations

10.1056/nejmoa1808783

Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial)

Umberto Benedetto, Douglas G. Altman, Stephen Gerry, Alastair Gray, Belinda Lees et al. (100 authors)

Journal of the American Heart Association2018-03-0412 citations

10.1161/jaha.117.007570

Associations Between Adding a Radial Artery Graft to Single and Bilateral Internal Thoracic Artery Grafts and Outcomes

David P. Taggart, Douglas G. Altman, Marcus Flather, Stephen Gerry, Alastair Gray et al. (7 authors)

Circulation2017-06-0164 citations

10.1161/circulationaha.117.027659

One-year costs of bilateral or single internal mammary grafts in the Arterial Revascularisation Trial

Alastair Gray, Jacqueline Murphy, Douglas G. Altman, Umberto Benedetto, Helen Campbell et al. (9 authors)

Heart2017-04-2717 citations

10.1136/heartjnl-2016-311058

Randomized Trial of Bilateral versus Single Internal-Thoracic-Artery Grafts

David P. Taggart, Douglas G. Altman, Alastair Gray, Belinda Lees, Stephen Gerry et al. (7 authors)

New England Journal of Medicine2016-11-14380 citations

10.1056/nejmoa1610021

Effects of on-pump and off-pump surgery in the Arterial Revascularization Trial

David P. Taggart, Douglas G. Altman, Alastair Gray, Belinda Lees, Fiona Nugara et al. (8 authors)

European Journal of Cardio-Thoracic Surgery2014-09-1242 citations

10.1093/ejcts/ezu349

Assessment of data quality in an international multi-centre randomised trial of coronary artery surgery.

Krzych LJ, Lees B, Nugara F, Banya W, Bochenek A, Cook J, Taggart D, Flather MD.

2011-09-262 citations

10.1186/1745-6215-12-212

Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART).

Taggart DP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM, Campbell H, Flather M, ART Investigators.

2010-08-30258 citations

10.1093/eurheartj/ehq318

Interventions

Current interventions as of 26/10/2021: Patients were randomised to single internal mammary artery (SIMA) grafting or bilateral internal mammary artery (BIMA) grafting with supplemental vein or radial

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Coronary artery bypass graft (CABG) patients with multi-vessel coronary artery disease (including urgent and off pump CABG patients)

Exclusion criteria

Exclusion criteria: 1. Single graft 2. Redo CABG 3. Evolving myocardial infarction 4. Concomitant valve surgery

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 26/10/2021: Survival will be measured using patient telephone follow-up or by national databases where applicable at 10 and 15 years. Previous primary outcome measure: Survival	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 26/10/2021: 1. Cause-specific mortality measured using patient telephone follow-up or by national databases where applicable at 10 and 15 years 2. Major Adverse Cardiovascular Events measured using patient telephone follow-up or by national databases where applicable at 15 years 3. 30 day mortality measured using patient telephone follow-up or by national databases where applicable at 30 days 4. Need for re-intervention by percutaneous coronary intervention or redo surgery other clinical events measured using patient telephone follow-up or by national databases where applicable at 10 years 5. Quality of life measured using the Short Form-36 (SF36), Rose, and EuroQol questionnaires at 10 years 6. Cost-effectiveness measured using patient telephone follow-up or by national databases where applicable at 10 years and (added 24/02/2026) 15 years Previous secondary outcome measures: 1. Cause-specific mortality 2. 30 day mortality 3. Need for re-intervention by percutaneous coronary intervention or redo surgery other clinical events 4. Quality of life (SF36, Rose and EuroQol) 5. Cost-effectiveness	—

Measure

Time frame

Current secondary outcome measures as of 26/10/2021: 1. Cause-specific mortality measured using patient telephone follow-up or by national databases where applicable at 10 and 15 years 2. Major Adverse Cardiovascular Events measured using patient telephone follow-up or by national databases where applicable at 15 years 3. 30 day mortality measured using patient telephone follow-up or by national databases where applicable at 30 days 4. Need for re-intervention by percutaneous coronary intervention or redo surgery other clinical events measured using patient telephone follow-up or by national databases where applicable at 10 years 5. Quality of life measured using the Short Form-36 (SF36), Rose, and EuroQol questionnaires at 10 years 6. Cost-effectiveness measured using patient telephone follow-up or by national databases where applicable at 10 years and (added 24/02/2026) 15 years Previous secondary outcome measures: 1. Cause-specific mortality 2. 30 day mortality 3. Need for re-intervention by percutaneous coronary intervention or redo surgery other clinical events 4. Quality of life (SF36, Rose and EuroQol) 5. Cost-effectiveness

—

Countries

Australia, Austria, Brazil, England, India, Italy, Poland, United Kingdom

Outcome results

None listed